Opinion
Video
Author(s):
Panelists discuss how the TRAILBLAZER-ALZ-2 trial demonstrates that donanemab significantly reduces amyloid plaques and slows cognitive and functional decline in early Alzheimer’s disease, with a manageable safety profile and the potential for faster plaque removal compared to other amyloid-targeting therapies.
Trial Design:
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.